.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,248,126

« Back to Dashboard

Details for Patent: 9,248,126

Title:Modulators of cellular adhesion
Abstract: The present invention provides compounds having formula (I): ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Inventor(s): Shen; Wang (San Mateo, CA), Barr; Kenneth (Boston, MA), Oslob; Johan D. (Sunnyvale, CA), Zhong; Min (Foster City, CA)
Assignee: SARCODE BIOSCIENCE INC. (Brisbane, CA)
Filing Date:Aug 19, 2013
Application Number:13/969,915
Claims:1. A pharmaceutical formulation comprising an LFA-1 antagonist, wherein the formulation is an inhalation formulation and wherein the LFA-1 antagonist comprises a compound of Formula I or its pharmaceutically acceptable salt or ester, having the following structure: ##STR00216## wherein R.sup.1 and R.sup.2 are each independently hydrogen, --(CH.sub.2).sub.mOH, --(CH.sub.2).sub.maryl, --(CH.sub.2).sub.mheteroaryl, wherein m is 0-6, --CH(R.sup.1A)(OR.sup.1B), --CH(R.sup.1A)(NHR.sup.1B), U-T-Q, or an aliphatic, alicyclic, heteroaliphatic or heteroalicyclic moiety optionally substituted with U-T-Q, wherein U is absent, --O--, --S(O).sub.0-2--, --SO.sub.2N(R.sup.1A), --N(R.sup.1A), --N(R.sup.1A)C(.dbd.O)--, --N(R.sup.1A)C(.dbd.O)--O--, --N(R.sup.1A)C(.dbd.O)--N(R.sup.1B)--, --N(R.sup.1A)--SO.sub.2--, --C(.dbd.O)--, --C(.dbd.O)--O--, --O--C(.dbd.O)--, aryl, heteroaryl, alkylaryl, alkylheteroaryl, --C(.dbd.O)--N(R.sup.1A)--, --O--C(.dbd.O)--N(R.sup.1A)--, --C(.dbd.N--R.sup.1E)--, --C(.dbd.N--R.sup.1E)--O--, --C(.dbd.N--R.sup.1E)--N(R.sup.1A)--, --O--C(.dbd.N--R.sup.1E)--N(R.sup.1A)--, --N(R.sup.1A)C(.dbd.N--R.sup.1E)--, --N(R.sup.1A)C(.dbd.N--R.sup.1E)--O--, N(R.sup.1A)C(.dbd.N--R.sup.1E)--N(R.sup.1B)--, --P(.dbd.O)(OR.sup.1A)--O--, or --P(.dbd.O)(R.sup.1A)--O--; T is absent, an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety; and Q is hydrogen, halogen, cyano, isocyanate, --OR.sup.1B, --SR.sup.1B; N(R.sup.1B).sub.2, --NHC(.dbd.O)OR.sup.1B, --NHC(.dbd.O)N(R.sup.1B).sub.2, --NHC(.dbd.O)R.sup.1B, --NHSO.sub.2R.sup.1B, --NHSO.sub.2N(R.sup.1B).sub.2, --NHSO.sub.2NHC(.dbd.O)OR.sup.1B, --NHC(.dbd.O)NHSO.sub.2R.sup.1B, --C(.dbd.O)NHC(.dbd.O)OR.sup.1B, --C(.dbd.O)NHC(.dbd.O)R.sup.1B, C(.dbd.O)NHC(.dbd.O)N(R.sup.1B).sub.2, --C(.dbd.O)NHSO.sub.2R.sup.1B, --C(.dbd.O)NHSO.sub.2N(R.sup.1B).sub.2, --C(.dbd.S)N(R.sup.1B).sub.2, --SO.sub.2R.sup.1B, --SO.sub.2--O--R.sup.1B, --SO.sub.2--N(R.sup.1B).sub.2, --SO.sub.2--NHC(.dbd.O)OR.sup.1B, --SO.sub.2--NHC(.dbd.O)--N(R.sup.1B).sub.2, --SO.sub.2--NHC(.dbd.O)R.sup.1B, --O--C(.dbd.O)N(R.sup.1B).sub.2, --O--C(.dbd.O)R.sup.1B, --O--C(.dbd.O)NHC(.dbd.O)R.sup.1B, --O--C(.dbd.O)NH--SO.sub.2R.sup.1B, --O--SO.sub.2R.sup.1B, or an aliphatic heteroaliphatic, aryl or heteroaryl moiety, or wherein R.sup.1 and R.sup.2 taken together are an alicyclic or heterocyclic moiety; wherein each occurrence of R.sup.1A and R.sup.1B is independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, --COR.sup.1C, or --CONR.sup.1CR.sup.1D; wherein each occurrence of R.sup.1C and R.sup.1D is independently hydrogen, hydroxyl, or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety; and R.sup.1E is hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, --CN, --OR.sup.1C, --NR.sup.1CR.sup.1D or --SO.sub.2R.sup.1C; R.sup.3 is --C(.dbd.O)OR.sup.3A, --C(.dbd.O)H, --CH.sub.2OR.sup.3A, --CH.sub.2O--C(.dbd.O)-alkyl, --C(.dbd.O)NH(R.sup.3A), --CH.sub.2X.sup.0; wherein each occurrence of R.sup.3A is independently hydrogen, a protecting group, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl or heteroalkylheteroaryl moiety, or R.sup.3A, taken together with R.sup.1 or R.sup.2, forms a heterocyclic moiety; wherein X.sup.0 is a halogen selected from F, Cl, Br or I; R.sup.4, for each occurrence, is independently hydrogen, halogen, --CN, --NO.sub.2, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--, --S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety; n is an integer from 0-4; AR.sup.1 is a monocyclic or polycyclic aryl, heteroaryl, alkylaryl, alkylheteroaryl, alicyclic or heterocyclic moiety; A, B, D and E are connected by single bonds; wherein D is N and each occurrence of A, B, and E is independently CHR.sup.i; wherein each occurrence of R.sup.i is independently hydrogen, halogen, --CN, --NO.sub.2, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, or is -GR.sup.G1 wherein G is --O--, --S--, --NR.sup.G2--, --CO--, --SO--, --SO.sub.2--, --C(.dbd.O)O--, --C(.dbd.O)NR.sup.G2--, --OC(.dbd.O)--, --NR.sup.G2C(.dbd.O)-- or --SO.sub.2NR.sup.G2--, and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, or any two adjacent occurrences of R.sup.i, taken together, represent an alicyclic, heteroalicyclic, aryl, or heteroaryl moiety; p is an integer from 0-4; and L is C.dbd.O or a substituted or unsubstituted C.sub.1-6alkylidene or C.sub.2-6alkenylidene chain wherein up to two non-adjacent methylene units are independently optionally replaced by --C(.dbd.O).

2. The formulation of claim 1, wherein the LFA-1 antagonist comprises a compound of Formula I' or its pharmaceutically acceptable salt or ester, having the following structure: ##STR00217## wherein R.sup.4A and R.sup.4B are independently a halogen selected from F, Cl, Br or I; and R.sup.B1, R.sup.B2 and R.sup.E are independently hydrogen or substituted or unsubstituted lower alkyl.

3. The formulation of claim 2, wherein the LFA-1 antagonist has one of the following formulae: ##STR00218##

4. The formulation of claim 1, wherein the compound is present in an amount effective to modulate adhesion between intracellular adhesion molecules and the leukocyte integrin family of receptors.

5. The formulation of claim 1, wherein the compound is present in an amount effective to antagonize CD11/CD18 receptors associated with leukocytes.

6. The formulation of claim 1, wherein the LFA-1 antagonist is a sodium, potassium, lithium, magnesium, or calcium salt.

7. The formulation of claim 1, wherein the formulation is in the form of a powder, solution, spray, or inhalant.

8. The formulation of claim 1, further comprising at least one additional therapeutic agent, wherein the additional therapeutic agent is selected from the group consisting of an anti-inflammatory agent, painkillers, antinausea medications, anti-sickness drugs, a MAC-1 modulator, and an LFA-1 modulator.

9. The formulation of claim 4, wherein said intracellular adhesion molecules are selected from ICAM-1, -2 and -3.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc